Based in Lexington, Mass., the Cystic Fibrosis Foundation Therapeutics Lab conducts groundbreaking CF research to help rapidly advance new therapies.
The journey to end cystic fibrosis isn't a straight line. It is an evolving map with many paths and unique challenges. It requires an ambitious research agenda to accelerate treatments and drug development for the underlying cause of the disease and ultimately deliver a cure.
The Cystic Fibrosis Foundation is the world's leader in the fight against CF, and our scientific portfolio reflects our drive to provide effective treatments and — one day — a cure to every individual with this disease.
Learn how your child's
This program is intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat cystic fibrosis with an emphasis on advancing CFTR gene repair and replacement approaches.
This competition is awarding one year of free lab and office space at Bakar Labs of University of California Berkeley to applicants with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may be applied to CF.
The patient-centered outcomes research (PCOR) training manual provides discrete steps, tools, and resources that CF Center research teams can take to integrate and maintain patient/caregiver-partners in CF research.
The intent of this request for applications is to solicit and fund projects that will improve our understanding of the biological basis for the development and progression of gastrointestinal manifestations in cystic fibrosis as well as to identify potential novel therapeutic strategies to manage and treat them.
The Research Additional Mentoring Program (RAMP) Award is designed to enable promising early-career physician scientists seeking additional research mentoring outside of their home academic institutions to enhance their clinical or translational research proficiency and support their development of the necessary clinical research capabilities to become independent investigators.
Cystic fibrosis occurs when the cystic fibrosis transmembrane conductance regulator (CFTR) protein is either not made correctly, or not made at all. By understanding how the protein is made, scientists have been able to develop treatments that target the protein and restore its function.